---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-048785"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:22:33.695654+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kintara Therapeutics enters into $2.85M ATM sales agreement with A.G.P.

## Summary
- Up to $2.85M of common stock may be offered and sold from time to time via Agent A.G.P./Alliance Global Partners.
- Agent receives 3.0% commission on gross proceeds; Company reimburses up to $50,000 in initial expenses.
- Initially reserved 685,096 shares based on $4.16 closing price on Sep 15, 2023.
- Sales may be made on Nasdaq Capital Market as 'at-the-market' under Rule 415; Company not obligated to sell.

## SEC filing metadata
- accession: 0000950170-23-048785
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/0000950170-23-048785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/ktra-20230919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-048785
- JSON: https://secwatch.observer/filing/0000950170-23-048785.json
- Plain text: https://secwatch.observer/filing/0000950170-23-048785.txt

## Key facts
- Material Agreements
  TuHURA Biosciences, Inc./NV entered into Sales Agreement with A.G.P./Alliance Global Partners valued at $2.85 million (effective 2023-09-19).
  - Action: entry
  - Agreement: atm program
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: $2.85 million
  - Effective: 2023-09-19
  source text: On September 19, 2023, Kintara Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2.85 million (“Shares”), subject to certain limitations on the amount of Common Stock that may be offered and sold by the Company set forth in the Sales Agreement (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/0000950170-23-048785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.